Ziopharm craters on report of patient death in gene therapy study
Shares of Ziopharm $ZIOP plunged this morning after Adam Feuerstein at TheStreet broke the story that one patient in its gene therapy study dubbed Ad-RTS-hIL-12 died due to an intracranial hemorrhage 15 days after starting treatment. The note on the death — one of several — was included in a slide presentation filed with the SEC. Notably, Feuerstein had the report even before FDA regulators were notified.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.